Inactive Instrument

Isofol Medical AB (publ) Share Price Nasdaq Stockholm

Equities

Pharmaceuticals

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Isofol Medical AB (publ)

Financials

Sales 2021 22.41M 2.07M 165M Sales 2022 12.8M 1.18M 94.3M Capitalization 120M 11.05M 881M
Net income 2021 -200M -18.49M -1.47B Net income 2022 -160M -14.79M -1.18B EV / Sales 2021 49.7 x
Net cash position 2021 378M 34.93M 2.78B Net cash position 2022 187M 17.26M 1.38B EV / Sales 2022 -5.24 x
P/E ratio 2021
-5.8 x
P/E ratio 2022
-0.75 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 62.57%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 72 01-08
Director of Finance/CFO 68 01-09
Chief Tech/Sci/R&D Officer 59 31/01/19
Members of the board TitleAgeSince
Chairman 83 -
Director/Board Member 76 01-03
Director/Board Member 74 31/12/17
More insiders
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
Calendar
More about the company